Metastatic osteosarcoma, patterns of care and outcomes of patients in a real‐life national setting over a decade
Metastatic osteosarcoma (MOS) has a poor prognosis, and few treatment options. This multicentre observational study provides real-world data on treatment patterns of patients with MOS in France. The primary objective was to describe treatment modalities of patients with MOS aged ≥12 years treated in 11 reference network centers. Secondary objectives were to assess time to next treatment (TTNT), overall survival (OS) and prognostic factors for TTNT and OS. From 2008 to 2018, 262 patients with MOS were included; 88 patients were metastatic at diagnosis, and 174 patients had a metastatic relapse. Median age at diagnosis was 26 (12-86). A total of 227 (86.6%) patients received systemic treatment in the metastatic setting, and 75 (28.6%) patients received more than two lines. Overall, 153 (58.4%) patients underwent at least a loco-regional procedure, and 50 patients (19.1%) participated in a clinical trial in the metastatic setting. Median OS from metastasis diagnosis was 21.5 months [95% CI 18.9-27.0], 23.0 months [95% CI 15.0-31.1] in the synchronous cohort, and 21.4 months [95% CI 18.7-29.7] in the metachronous cohort. Median TTNT was 8.2 months [95% CI 6.7-9.9], 5.7 months [95% CI 4.2-7.2], 3.7 months [95% CI 3.0-4.3], and 2.9 months [95% CI 1.8-3.9] in first, second, third, and fourth line. It was 7.6 months [95% CI 5.1-12.5], 6 months [95% CI 3.6-8.7], and 4.8 months [95% CI 2.9-7.5] for tyrosine kinase inhibitors such as regorafenib or cabozantinib in first, second, and third line. In MOS, the benefit of chemotherapy after first line is limited. TKIs show encouraging activity from first line. Inclusion in clinical trials should be prioritized.
Authors
- Axel Le Cesne
- Sophie Piperno‐Neumann (ORCID: https://orcid.org/0000-0001-9915-2810)
- Justine Gantzer (ORCID: https://orcid.org/0000-0002-3293-4903)
- Perrine Marec‐Bérard (ORCID: https://orcid.org/0000-0001-5315-5864)
- Hélène Bellio
- M. Reich (ORCID: https://orcid.org/0000-0003-1590-8057)
- Pascaline Boudou‐Rouquette (ORCID: https://orcid.org/0000-0002-4860-305X)
- Thibaud Valentin (ORCID: https://orcid.org/0000-0002-3189-8445)
- Myriam Jean‐Denis (ORCID: https://orcid.org/0000-0002-7885-7421)
- Carine Bellera (ORCID: https://orcid.org/0000-0001-7926-4671)
- Maxime Brunet (ORCID: https://orcid.org/0000-0002-7517-4529)
- Juliane Berchoud
- Simon Nannini (ORCID: https://orcid.org/0000-0003-3097-727X)
- Nathalie Gaspar (ORCID: https://orcid.org/0000-0002-1827-8903)
- Derek Dinart (ORCID: https://orcid.org/0000-0003-1815-3016)
- François Goldwasser (ORCID: https://orcid.org/0000-0002-7128-6128)
- Richard Duong
- Raul Perret (ORCID: https://orcid.org/0000-0003-2698-0249)
- Mehdi Brahmi (ORCID: https://orcid.org/0000-0001-9904-166X)
- Emmanuelle Bompas (ORCID: https://orcid.org/0000-0003-4414-7760)
- Maud Toulmonde (ORCID: https://orcid.org/0000-0003-3896-9274)
- Philippe Anract
- Bérengère Narciso
- Sarah Winter
- M Bonneau
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Institut de Cancérologie Strasbourg (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Bordeaux Population Health (FR)
- Hôpital Pellegrin (FR)
- Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale (FR)
- Institut Bergonié (FR)
- Institut Cochin (FR)
- Institut Curie (FR)
Publication Details
- Journal
- International Journal of Cancer
- Published
- 2025-09-28
- DOI
- https://doi.org/10.1002/ijc.70157
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00